Pharmacogenomics Technology Market, 2028- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented By Therapeutic Area (Oncology ( lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others), Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, Others), By Technology (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others), By Region, By Competition.

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2024-2028

Market Size (2022)

USD 6.46 billion

CAGR (2023-2028)

8.48%

Fastest Growing Segment

Oncology

Largest Market

North America

Market Overview

The Global Pharmacogenomics Technology Market has valued at USD 6.46 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.48% through 2028. In the ever-evolving landscape of healthcare and medicine, personalized treatment approaches have become a driving force in improving patient outcomes and reducing adverse drug reactions. One groundbreaking field that is at the forefront of this transformation is pharmacogenomics. This technology, often referred to as "PGx," holds the promise of tailoring medication regimens to an individual's genetic makeup, thus optimizing drug efficacy and minimizing adverse effects.

Pharmacogenomics is a branch of genomics that focuses on how an individual's genetic makeup influences their response to drugs. Every person's DNA is unique, and these genetic variations can impact how they metabolize and react to medications. By studying these genetic differences, pharmacogenomics aims to identify genetic markers that can predict a patient's response to a particular drug. This information can then be used to personalize treatment plans, ensuring that patients receive the most effective and safe medications.

Global Pharmacogenomics Technology is an umbrella term that encompasses the widespread application of pharmacogenomics on a global scale. Its goal is to incorporate pharmacogenomic information into routine clinical practice and drug development processes, ultimately benefiting patients worldwide. Global Pharmacogenomics Technology enables healthcare providers to make more informed decisions about which drugs are most suitable for each patient. By analyzing an individual's genetic profile, doctors can prescribe medications with greater confidence in their effectiveness and safety. Pharmaceutical companies are increasingly integrating pharmacogenomic data into their drug development processes. This allows for the identification of potential responders and non-responders during clinical trials, streamlining the drug development pipeline and reducing the risk of late-stage failures. Adverse drug reactions (ADRs) are a significant public health concern. Pharmacogenomics can help identify patients at risk of ADRs, allowing for dose adjustments or alternative medications to prevent these reactions and improve patient safety. As technology and data sharing improve, pharmacogenomic information becomes more accessible to healthcare professionals worldwide. This accessibility levels the playing field, ensuring that patients in resource-limited areas can also benefit from personalized medicine.

Key Market Drivers

Rising Chronic Disease Prevalence is Driving the Global Pharmacogenomics Technology Market

Chronic diseases have become a global health crisis, affecting millions of individuals and placing an enormous burden on healthcare systems worldwide. Conditions like heart disease, diabetes, cancer, and neurological disorders are on the rise, leading to increased morbidity, mortality, and healthcare costs. In response to this growing challenge, the field of pharmacogenomics is emerging as a vital tool for personalized medicine, offering new hope in the fight against chronic diseases.

The world is witnessing a significant rise in the prevalence of chronic diseases. Factors contributing to this crisis include an aging population, unhealthy lifestyle choices, and environmental factors. Chronic diseases are not only responsible for a substantial portion of global mortality but also impose a tremendous economic burden. According to the World Health Organization (WHO), non-communicable diseases (NCDs) are estimated to cause approximately 71% of all deaths worldwide, with an associated economic cost projected to exceed $30 trillion by 2030. One of the key benefits of pharmacogenomics is its ability to customize treatment plans for individual patients. By analyzing a patient's genetic profile, healthcare providers can identify the most suitable medications and dosages, leading to more effective therapies and better patient outcomes. For conditions like cancer, where treatment response can vary widely among individuals, pharmacogenomics can guide the selection of chemotherapy agents that are more likely to be effective based on a patient's genetic profile, leading to better outcomes and fewer unnecessary side effects. Tailoring medications to a patient's genetic profile can lead to more efficient healthcare spending. By avoiding trial-and-error approaches to drug therapy, healthcare systems can reduce the cost of ineffective treatments, hospitalizations, and emergency room visits.

While pharmacogenomics holds immense potential, it is not without its challenges. Widespread adoption of this technology requires substantial investments in infrastructure, education, and genetic testing capabilities. Additionally, ethical concerns related to genetic privacy and data security must be addressed. Despite these challenges, the global pharmacogenomics market is expected to experience significant growth in the coming years. Advances in DNA sequencing technologies, increased awareness among healthcare professionals, and a growing body of research supporting the clinical utility of pharmacogenomics are driving this expansion.

The rising prevalence of chronic diseases is placing an unprecedented strain on healthcare systems worldwide. In this context, pharmacogenomics technology offers a glimmer of hope. By tailoring medical treatments to an individual's genetic makeup, pharmacogenomics has the potential to revolutionize the management of chronic diseases, improve patient outcomes, and reduce healthcare costs. As research continues to advance and healthcare systems integrate this technology, we can look forward to a future where personalized medicine becomes the standard of care, offering new solutions to the global chronic disease crisis.


Download Free Sample Report

Rising Pharmaceutical Industry Investment Fuels Growth in Global Pharmacogenomics Technology

The pharmaceutical industry has always been at the forefront of innovation and research in medicine. In recent years, there has been a significant surge in investments in pharmacogenomics technology, a field that holds immense promise for revolutionizing drug development and personalized medicine. Pharmacogenomics, the study of how an individual's genetic makeup influences their response to drugs, is poised to reshape the way we approach healthcare.

The impact of rising investment in pharmacogenomics technology extends beyond the pharmaceutical industry. As pharmacogenomics becomes more integrated into clinical practice, patients will benefit from more effective and personalized treatment plans. This will lead to better health outcomes, reduced adverse effects, and increased patient satisfaction. Personalized medicine can lead to more efficient resource allocation within healthcare systems. By tailoring treatments to individuals, unnecessary treatments and hospitalizations can be minimized, ultimately reducing healthcare costs. Pharmacogenomics has the potential to enhance drug safety by identifying patients at higher risk of adverse reactions. This can lead to better labeling and monitoring of medications, further ensuring patient safety.

The pharmaceutical industry's increasing investment in pharmacogenomics technology is poised to reshape the future of medicine. As the field continues to advance, we can expect to see a shift towards personalized medicine, where treatments are tailored to an individual's genetic makeup. This not only benefits patients by improving treatment outcomes but also offers pharmaceutical companies a competitive edge in drug development. The global impact of pharmacogenomics extends beyond the pharmaceutical industry, with the potential to improve healthcare efficiency and reduce costs. As such, the rising investment in pharmacogenomics technology is a positive step towards a more personalized and effective approach to healthcare. 

Key Market Challenges

Data Complexity and Integration

One of the most significant challenges in pharmacogenomics technology is dealing with the vast and complex datasets generated by genomic sequencing and drug response studies. Analyzing and integrating these datasets effectively is essential for identifying genetic markers that can predict drug responses accurately. This requires advanced computational tools and expertise in bioinformatics, which are not readily available in all regions of the world.

Ethical and Privacy Concerns

As pharmacogenomic data becomes more accessible and widespread, concerns about patient privacy and data security have grown. The sharing of genomic information for research purposes must be carefully regulated to protect patient rights and confidentiality. Striking a balance between advancing research and ensuring ethical conduct is a constant challenge in the global pharmacogenomics landscape.

Standardization and Data Sharing

Pharmacogenomics research often relies on data from multiple sources, including academic institutions, pharmaceutical companies, and healthcare providers. To harness the full potential of pharmacogenomics, these entities must adopt standardized data formats and data sharing protocols. Achieving this standardization on a global scale is a significant challenge, as different regions have their own data protection laws and research regulations.

Healthcare Disparities

Global pharmacogenomics technology faces a unique set of challenges in addressing healthcare disparities. Access to advanced genomic testing and personalized medicine can be limited in low-resource settings, creating a gap in patient care. Bridging this divide requires significant investment in infrastructure, training, and resources, which may not be readily available in all regions.

Regulatory Hurdles

Regulatory agencies play a crucial role in ensuring the safety and efficacy of drugs. However, the integration of pharmacogenomic data into drug development and clinical practice has raised questions about how best to regulate these advances. Regulatory bodies around the world must adapt to accommodate the rapidly evolving field of pharmacogenomics, which can be a slow and complex process.

Education and Training

The successful implementation of pharmacogenomics technology depends on a well-trained workforce of scientists, clinicians, and healthcare providers who understand the intricacies of genomics and its application in medicine. Providing adequate education and training opportunities for professionals in regions with limited resources can be challenging but is essential for the widespread adoption of pharmacogenomics.

Cost and Reimbursement

The cost of genomic testing and personalized medicine can be prohibitive for some patients and healthcare systems. Developing cost-effective testing methods and ensuring reimbursement for pharmacogenomic services are ongoing challenges that must be addressed to make personalized medicine accessible to all.

Key Market Trends

Technological Advancements

In the ever-evolving landscape of healthcare, the integration of cutting-edge technology has become a catalyst for transformation. One field where this transformation is particularly evident is pharmacogenomics, a discipline that combines genetics and pharmacology to tailor medical treatments to an individual's genetic makeup. Recent years have witnessed a surge in technological advancements that are propelling the global pharmacogenomics technology market to new heights.

One of the most significant technological advancements in pharmacogenomics is high-throughput sequencing, commonly known as next-generation sequencing (NGS). NGS allows for rapid and cost-effective sequencing of an individual's entire genome or specific gene regions. This technology has revolutionized the field by enabling researchers and clinicians to identify genetic variations with unprecedented accuracy and efficiency. The abundance of genomic data generated by NGS has given rise to the need for robust data analysis tools. Machine learning algorithms have emerged as a powerful tool for interpreting complex genetic data. These algorithms can identify patterns, predict drug responses, and help healthcare providers make informed treatment decisions. The integration of big data analytics and machine learning is transforming pharmacogenomics into a data-driven discipline. The development of comprehensive pharmacogenomics databases, such as the Pharmacogenomics Knowledge Base (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC), has been instrumental in advancing pharmacogenomics research and implementation. These databases aggregate vast amounts of genetic and drug response data, providing valuable resources for healthcare professionals to make informed decisions about drug prescribing.

Advancements in point-of-care testing devices are bringing pharmacogenomics closer to the patient. These devices can quickly analyze genetic markers and provide immediate guidance on drug selection and dosing, allowing healthcare providers to make real-time decisions at the bedside. This technology is particularly valuable in emergency situations and critical care settings. Telehealth and mobile applications are expanding access to pharmacogenomic information and services. Patients can now access their genetic data and consult with healthcare providers remotely. Mobile apps provide user-friendly interfaces for both patients and clinicians to interpret genetic test results and make informed treatment choices.

The integration of these technological advancements into pharmacogenomics is transforming the way healthcare is delivered. Patients receive tailored treatment plans based on their genetic makeup, increasing the likelihood of treatment success and reducing adverse drug reactions. By optimizing drug selection and dosing, pharmacogenomics helps reduce healthcare costs associated with ineffective or harmful medications. Pharmacogenomics technology enables healthcare providers to make informed decisions, leading to better patient outcomes and quality of life. Pharmacogenomics reduces the need for trial-and-error prescribing, minimizing patient suffering and potentially life-threatening situations.

Segmental Insights

Therapeutic Area Insights

Based on the therapeutic area, the oncology segment emerged as the dominant player in the global market for Pharmacogenomics Technology in 2022. Cancer is a leading cause of mortality worldwide, and its incidence continues to rise due to various factors such as aging populations, lifestyle changes, and environmental factors. The high prevalence of cancer creates a substantial demand for pharmacogenomics technologies to develop personalized treatments. Oncology is a field that heavily relies on understanding the genetic variations and mutations that drive cancer development and progression. Pharmacogenomics plays a crucial role in identifying specific genetic markers associated with various cancer types, which can guide targeted therapies. The concept of precision medicine involves tailoring medical treatment to individual patients based on their genetic makeup. In oncology, identifying specific genetic mutations and variations helps oncologists select the most effective therapies and predict treatment responses, reducing the likelihood of adverse effects. Pharmaceutical companies invest heavily in pharmacogenomics research to discover and develop targeted cancer therapies. By understanding the genetic factors that influence drug responses, these companies can design more effective and safer cancer drugs, which drives the adoption of pharmacogenomics technologies. Many governments and regulatory bodies worldwide have recognized the potential of pharmacogenomics in improving cancer treatment outcomes. They may provide funding, incentives, or regulatory support to encourage the integration of pharmacogenomics into oncology practices. Oncology research and clinical trials often incorporate pharmacogenomics to identify biomarkers for patient stratification and to assess treatment efficacy. This drives the demand for advanced pharmacogenomics technologies and services in both research and clinical settings.

Technology Insights

The Polymerase Chain Reaction (PCR) segment is projected to experience rapid growth during the forecast period. PCR is a highly sensitive and specific technique for amplifying DNA. This precision is essential in pharmacogenomics, where researchers and clinicians need accurate and reliable data about genetic variations and their effects on drug response. PCR allows for the selective amplification of specific DNA regions of interest. PCR is easily scalable, making it suitable for various applications within pharmacogenomics, from research and development to clinical diagnostics. It can be adapted to analyze a wide range of DNA targets and accommodate various sample sizes. PCR technology enables rapid DNA amplification, allowing researchers to process a large number of samples quickly. This efficiency is crucial for high-throughput pharmacogenomics studies and clinical testing, where timely results are essential. PCR can be used for different types of pharmacogenomics analyses, such as genotyping, gene expression profiling, and mutation detection. This versatility makes it a valuable tool for studying various aspects of personalized medicine. PCR has been widely used in molecular biology and genetics for decades. Its well-established protocols and a robust body of knowledge make it a trusted choice in pharmacogenomics research and diagnostics. PCR technology has become more cost-effective over the years, making it accessible to a broader range of research institutions and clinical laboratories. This affordability contributes to its dominance in the market. PCR-based assays have received regulatory approval for use in clinical diagnostics, enhancing their credibility and adoption in pharmacogenomics testing. PCR can be integrated with other technologies and platforms, such as next-generation sequencing (NGS) and microarray analysis, to provide comprehensive pharmacogenomic insights. This integration capability enhances its utility. PCR assays can be customized to target specific genes or genomic regions of interest, allowing researchers to tailor their analyses to the requirements of a particular pharmacogenomics study or clinical application. As personalized medicine gains traction, the demand for pharmacogenomic testing and research continues to grow. PCR technology, with its precision and speed, is well-suited to support the goals of personalized medicine by identifying genetic factors that influence drug response.


Download Free Sample Report

Regional Insights

North America emerged as the dominant player in the global Pharmacogenomics Technology market in 2022, holding the largest market share in terms of value. North America, particularly the United States, boasts a robust infrastructure for research and development in the pharmaceutical and biotechnology sectors. The presence of leading pharmaceutical companies, academic institutions, and government agencies like the National Institutes of Health (NIH) has fostered significant advancements in pharmacogenomics research and technology development. North America has attracted substantial investment in biotechnology and genomics research, including pharmacogenomics. This investment has facilitated the development of cutting-edge technologies and therapies that leverage genomic information to tailor drug treatments. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) have been proactive in supporting pharmacogenomics research and its integration into clinical practice. Clear regulatory guidelines and incentives for pharmacogenomic research have encouraged innovation and adoption. North America has access to extensive genetic data due to a large population base and the availability of genomic databases like the Genomic Data Commons. This wealth of genetic information supports pharmacogenomics research and the development of personalized medicine approaches. North America has a culture of collaboration between academia, industry, and government organizations. This collaborative environment fosters the exchange of ideas, expertise, and resources, accelerating the translation of pharmacogenomics discoveries into clinical applications.

Recent Developments

  • In April 2023, Leica Biosystems obtained approval for the BOND MMR Antibody Panel, a development aimed at assisting customers by providing the option of IHC Mismatch Repair (MMR) when examining patients with colorectal cancer who could potentially have Lynch syndrome.
  • In December 2022, MapMyGenome introduced an economical pharmacogenomics offering called MedicaMap. MedicaMap, a state-of-the-art pharmacogenomic solution developed by MapMyGenome, evaluates how a person reacts to medications by examining their genetic profile. This comprehensive pharmacogenomic solution assesses over 165 drugs approved by the US FDA across a wide range of medical fields, including psychiatry, oncology, cardiology, diabetology, and several others.
  • In September 2021, Thermo Fisher Scientific Inc. introduced the QuantStudio Absolute Q Digital PCR System, a comprehensive digital PCR (dPCR) technology capable of swiftly producing highly accurate results. This system eliminates the need for intricate, multi-instrument procedures by merging microfluidic array technology with simplified processes, ultimately enhancing both data consistency and precision.

Key Market Players

  • QIAGEN N.V.
  • GE HealthCare,
  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd
  • FOUNDATION MEDICINE, INC.
  • Thermo Fisher Scientific Inc.
  • Leica Biosystems Nussloch GmBH,
  • Pfizer Inc.

 By Therapeutic Area

By Technology

By Region
  • Oncology
  • Neurological Disorders
  • Cardiovascular Disease
  • Immunological Disorders
  • Infectious Diseases
  • Others
  • PCR
  • In-situ Hybridization Immunohistochemistry
  • Sequencing
  • Others
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

 

Report Scope:

In this report, the Global Pharmacogenomics Technology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Pharmacogenomics Technology Market, By Therapeutic Area:

o   Oncology

o   Neurological Disorders

o   Cardiovascular Disease

o   Immunological Disorders

o   Infectious Diseases

o   Others

  • Pharmacogenomics Technology Market, By Technology:

o   PCR

o   In-situ Hybridization

o   Immunohistochemistry

o   Sequencing

o   Others

  • Pharmacogenomics Technology Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharmacogenomics Technology Market.

Available Customizations:

Global Pharmacogenomics Technology market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
Global Pharmacogenomics Technology Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.    Markets Covered

1.2.2.     Years Considered for Study

1.2.3.    Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

4.    Voice of Customer

5.    Global Pharmacogenomics Technology Market Outlook

5.1.  Market Size & Forecast

5.1.1.    By Value

5.2.  Market Share & Forecast

5.2.1.    By Therapeutic Area (Oncology ( lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others), Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, Others)

5.2.2.    By Technology (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others)

5.2.3.    By Region

5.2.4.    By Company (2022)

5.3.  Market Map

6.    North America Pharmacogenomics Technology Market Outlook

6.1.  Market Size & Forecast

6.1.1.    By Value

6.2.  Market Share & Forecast

6.2.1.    By Therapeutic Area

6.2.2.    By Technology

6.2.3.    By Country

6.3.  North America: Country Analysis

6.3.1.    United States Pharmacogenomics Technology Market Outlook

6.3.1.1.        Market Size & Forecast

6.3.1.1.1.           By Value

6.3.1.2.        Market Share & Forecast

6.3.1.2.1.           By Therapeutic Area

6.3.1.2.2.           By Technology

6.3.2.    Canada Pharmacogenomics Technology Market Outlook

6.3.2.1.        Market Size & Forecast

6.3.2.1.1.           By Value

6.3.2.2.        Market Share & Forecast

6.3.2.2.1.           By Therapeutic Area

6.3.2.2.2.           By Technology

6.3.3.    Mexico Pharmacogenomics Technology Market Outlook

6.3.3.1.        Market Size & Forecast

6.3.3.1.1.           By Value

6.3.3.2.        Market Share & Forecast

6.3.3.2.1.           By Therapeutic Area

6.3.3.2.2.           By Technology

7.    Europe Pharmacogenomics Technology Market Outlook

7.1.  Market Size & Forecast

7.1.1.    By Value

7.2.  Market Share & Forecast

7.2.1.    By Therapeutic Area

7.2.2.    By Technology

7.3.  Europe: Country Analysis

7.3.1.    Germany Pharmacogenomics Technology Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.           By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.           By Therapeutic Area

7.3.1.2.2.           By Technology

7.3.2.    United Kingdom Pharmacogenomics Technology Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.           By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.           By Therapeutic Area

7.3.3.    Italy Pharmacogenomics Technology Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.           By Value

7.3.3.2.        Market Share & Forecast

7.3.3.2.1.           By Therapeutic Area

7.3.3.2.2.           By Technology

7.3.4.    France Pharmacogenomics Technology Market Outlook

7.3.4.1.        Market Size & Forecast

7.3.4.1.1.           By Value

7.3.4.2.        Market Share & Forecast

7.3.4.2.1.           By Therapeutic Area

7.3.4.2.2.           By Technology

7.3.5.    Spain Pharmacogenomics Technology Market Outlook

7.3.5.1.        Market Size & Forecast

7.3.5.1.1.           By Value

7.3.5.2.        Market Share & Forecast

7.3.5.2.1.           By Therapeutic Area

7.3.5.2.2.           By Technology

8.    Asia-Pacific Pharmacogenomics Technology Market Outlook

8.1.  Market Size & Forecast

8.1.1.    By Value

8.2.  Market Share & Forecast

8.2.1.    By Therapeutic Area

8.2.2.    By Technology

8.3.  Asia-Pacific: Country Analysis

8.3.1.    China Pharmacogenomics Technology Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.           By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.           By Therapeutic Area

8.3.1.2.2.           By Technology

8.3.2.    India Pharmacogenomics Technology Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.           By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.           By Therapeutic Area

8.3.2.2.2.           By Technology

8.3.3.    Japan Pharmacogenomics Technology Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.           By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.           By Therapeutic Area

8.3.3.2.2.           By Technology

8.3.4.    South Korea Pharmacogenomics Technology Market Outlook

8.3.4.1.        Market Size & Forecast

8.3.4.1.1.           By Value

8.3.4.2.        Market Share & Forecast

8.3.4.2.1.           By Therapeutic Area

8.3.4.2.2.           By Technology

8.3.5.    Australia Pharmacogenomics Technology Market Outlook

8.3.5.1.        Market Size & Forecast

8.3.5.1.1.           By Value

8.3.5.2.        Market Share & Forecast

8.3.5.2.1.           By Therapeutic Area

8.3.5.2.2.           By Technology

9.    South America Pharmacogenomics Technology Market Outlook

9.1.  Market Size & Forecast

9.1.1.    By Value

9.2.  Market Share & Forecast

9.2.1.    By Therapeutic Area

9.2.2.    By Technology

9.3.  South America: Country Analysis

9.3.1.    Brazil Pharmacogenomics Technology Market Outlook

9.3.1.1.        Market Size & Forecast

9.3.1.1.1.           By Value

9.3.1.2.        Market Share & Forecast

9.3.1.2.1.           By Therapeutic Area

9.3.1.2.2.           By Technology

9.3.2.    Argentina Pharmacogenomics Technology Market Outlook

9.3.2.1.        Market Size & Forecast

9.3.2.1.1.           By Value

9.3.2.2.        Market Share & Forecast

9.3.2.2.1.           By Therapeutic Area

9.3.2.2.2.           By Technology

9.3.3.    Colombia Pharmacogenomics Technology Market Outlook

9.3.3.1.        Market Size & Forecast

9.3.3.1.1.           By Value

9.3.3.2.        Market Share & Forecast

9.3.3.2.1.           By Therapeutic Area

9.3.3.2.2.           By Technology

10. Middle East and Africa Pharmacogenomics Technology Market Outlook

10.1.   Market Size & Forecast        

10.1.1. By Value

10.2.   Market Share & Forecast

10.2.1. By Therapeutic Area

10.2.2. By Technology

10.3.   MEA: Country Analysis

10.3.1. South Africa Pharmacogenomics Technology Market Outlook

10.3.1.1.     Market Size & Forecast

10.3.1.1.1.         By Value

10.3.1.2.     Market Share & Forecast

10.3.1.2.1.         By Therapeutic Area

10.3.1.2.2.         By Technology

10.3.2. Saudi Arabia Pharmacogenomics Technology Market Outlook

10.3.2.1.     Market Size & Forecast

10.3.2.1.1.         By Value

10.3.2.2.     Market Share & Forecast

10.3.2.2.1.         By Therapeutic Area

10.3.2.2.2.         By Technology

10.3.3. UAE Pharmacogenomics Technology Market Outlook

10.3.3.1.     Market Size & Forecast

10.3.3.1.1.         By Value

10.3.3.2.     Market Share & Forecast

10.3.3.2.1.         By Therapeutic Area

10.3.3.2.2.         By Technology

11. Market Dynamics

11.1.   Drivers

11.2.   Challenges

12. Market Trends & Developments

12.1.   Merger & Acquisition

12.2.   Product Development

12.3.   Recent Developments

13. Global Pharmacogenomics Technology Market: SWOT Analysis

14. Competitive Landscape

14.1.   Business Overview

14.2.   Application Offerings

14.3.   Recent Developments

14.4.   Key Personnel

14.5.   SWOT Analysis

14.5.1. QIAGEN N.V.

14.5.2. GE HealthCare,

14.5.3. Agilent Technologies, Inc.

14.5.4. F. Hoffmann-La Roche Ltd

14.5.5. FOUNDATION MEDICINE, INC.

14.5.6. Thermo Fisher Scientific Inc.

14.5.7. Leica Biosystems Nussloch GmBH,

14.5.8. Pfizer Inc.

15. Strategic Recommendations

16. About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Pharmacogenomics Technology Market was estimated to be USD 6.46 billion in 2022.

down-arrow

The oncology segment demonstrated significant dominance in 2022 . The oncology pharmacogenomics market offers substantial revenue potential due to the high cost of cancer treatment and the willingness of patients and healthcare providers to invest in personalized therapies that offer better outcomes and reduced side effects.

down-arrow

QIAGEN N.V., GE HealthCare, Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd, FOUNDATION MEDICINE, INC., Thermo Fisher Scientific Inc., Leica Biosystems Nussloch GmBH,, Pfizer Inc. are the top players operating in the Global Pharmacogenomics Technology Market in 2022.

down-arrow

Rising chronic disease prevalence and growing pharmaceutical industry investment are the major drivers for the Global Pharmacogenomics Technology Market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Pharmacogenomics Technology Market to Grow with a CAGR of 8.48% through 2028

Sep, 2023

Rising chronic disease prevalence and growing pharmaceutical industry investment are factors driving the Global Pharmacogenomics Technology Market in the forecast period 2024-2028.

Why Choose Us